Taxotere 306 fázis III vizsgálat eredményei elorehaladott, áttétes emlorák elso vonalbeli kezelésében

Translated title of the contribution: Taxotere phase III trial on the first-line treatment of metastatic breast cancer

T. Pintér, Kofi Agyemang Prempeh, J. Szántó

Research output: Contribution to journalArticle

Abstract

Objectives: Doxorubicin and taxanes are the most effective agents in the treatment of advanced breast cancer. The aim of the study was to compare the efficacy of Doxorubicin (A) + Docetaxel (T) (AT) and standard Doxorubicin (A) + Cyclophosphamide (C) (AC) chemotherapy. Material and methods: Results of first-line AT (50/75 mg/m2) and AC (60/600 mg/m2) D 1 q 3 wk, maximum of 8 cycles, were compared. Three Hungarian centers - Petz Aladár County Teaching Hospital, Gyor, St. Margit Hospital, Budapest, and BAZ County Hospital, Miskolc, with 33 patients participated the international, phase III randomized TAX 306 trial. Between June, 1996 and March, 1998, 429 metastatic breast cancer patients were enrolled in the study. Eligible patients were who had not received prior chemotherapy for advanced disease, and were anthracycline-naive. Objective response rate observed in the AT arm was significantly higher than in the AC arm (ORR: 60% vs. 47%, p=0.008). Time to progression was longer in the AT group (37.1 weeks vs. 31.9 weeks, p=0.0153). Except for higher incidence of neutropenia not requiring dose modification in the AT arm, there were no major differences concerning toxicity. T did not enhance cardiac toxicity induced by A. Conclusion: AT results in significantly higher response rate and longer time to progression than AC in advanced breast cancer, even in patients with unfavourable prognosis.

Original languageHungarian
Pages (from-to)75-78
Number of pages4
JournalMagyar Onkologia
Volume44
Issue number1
Publication statusPublished - 2000

Fingerprint

docetaxel
Breast Neoplasms
Cyclophosphamide
Doxorubicin
County Hospitals
Therapeutics
Drug Therapy
Taxoids
Anthracyclines
Neutropenia
Teaching Hospitals

ASJC Scopus subject areas

  • Oncology

Cite this

Taxotere 306 fázis III vizsgálat eredményei elorehaladott, áttétes emlorák elso vonalbeli kezelésében. / Pintér, T.; Prempeh, Kofi Agyemang; Szántó, J.

In: Magyar Onkologia, Vol. 44, No. 1, 2000, p. 75-78.

Research output: Contribution to journalArticle

@article{e68aced2acea4cd3b519ba2329a3cd21,
title = "Taxotere 306 f{\'a}zis III vizsg{\'a}lat eredm{\'e}nyei elorehaladott, {\'a}tt{\'e}tes emlor{\'a}k elso vonalbeli kezel{\'e}s{\'e}ben",
abstract = "Objectives: Doxorubicin and taxanes are the most effective agents in the treatment of advanced breast cancer. The aim of the study was to compare the efficacy of Doxorubicin (A) + Docetaxel (T) (AT) and standard Doxorubicin (A) + Cyclophosphamide (C) (AC) chemotherapy. Material and methods: Results of first-line AT (50/75 mg/m2) and AC (60/600 mg/m2) D 1 q 3 wk, maximum of 8 cycles, were compared. Three Hungarian centers - Petz Alad{\'a}r County Teaching Hospital, Gyor, St. Margit Hospital, Budapest, and BAZ County Hospital, Miskolc, with 33 patients participated the international, phase III randomized TAX 306 trial. Between June, 1996 and March, 1998, 429 metastatic breast cancer patients were enrolled in the study. Eligible patients were who had not received prior chemotherapy for advanced disease, and were anthracycline-naive. Objective response rate observed in the AT arm was significantly higher than in the AC arm (ORR: 60{\%} vs. 47{\%}, p=0.008). Time to progression was longer in the AT group (37.1 weeks vs. 31.9 weeks, p=0.0153). Except for higher incidence of neutropenia not requiring dose modification in the AT arm, there were no major differences concerning toxicity. T did not enhance cardiac toxicity induced by A. Conclusion: AT results in significantly higher response rate and longer time to progression than AC in advanced breast cancer, even in patients with unfavourable prognosis.",
author = "T. Pint{\'e}r and Prempeh, {Kofi Agyemang} and J. Sz{\'a}nt{\'o}",
year = "2000",
language = "Hungarian",
volume = "44",
pages = "75--78",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "1",

}

TY - JOUR

T1 - Taxotere 306 fázis III vizsgálat eredményei elorehaladott, áttétes emlorák elso vonalbeli kezelésében

AU - Pintér, T.

AU - Prempeh, Kofi Agyemang

AU - Szántó, J.

PY - 2000

Y1 - 2000

N2 - Objectives: Doxorubicin and taxanes are the most effective agents in the treatment of advanced breast cancer. The aim of the study was to compare the efficacy of Doxorubicin (A) + Docetaxel (T) (AT) and standard Doxorubicin (A) + Cyclophosphamide (C) (AC) chemotherapy. Material and methods: Results of first-line AT (50/75 mg/m2) and AC (60/600 mg/m2) D 1 q 3 wk, maximum of 8 cycles, were compared. Three Hungarian centers - Petz Aladár County Teaching Hospital, Gyor, St. Margit Hospital, Budapest, and BAZ County Hospital, Miskolc, with 33 patients participated the international, phase III randomized TAX 306 trial. Between June, 1996 and March, 1998, 429 metastatic breast cancer patients were enrolled in the study. Eligible patients were who had not received prior chemotherapy for advanced disease, and were anthracycline-naive. Objective response rate observed in the AT arm was significantly higher than in the AC arm (ORR: 60% vs. 47%, p=0.008). Time to progression was longer in the AT group (37.1 weeks vs. 31.9 weeks, p=0.0153). Except for higher incidence of neutropenia not requiring dose modification in the AT arm, there were no major differences concerning toxicity. T did not enhance cardiac toxicity induced by A. Conclusion: AT results in significantly higher response rate and longer time to progression than AC in advanced breast cancer, even in patients with unfavourable prognosis.

AB - Objectives: Doxorubicin and taxanes are the most effective agents in the treatment of advanced breast cancer. The aim of the study was to compare the efficacy of Doxorubicin (A) + Docetaxel (T) (AT) and standard Doxorubicin (A) + Cyclophosphamide (C) (AC) chemotherapy. Material and methods: Results of first-line AT (50/75 mg/m2) and AC (60/600 mg/m2) D 1 q 3 wk, maximum of 8 cycles, were compared. Three Hungarian centers - Petz Aladár County Teaching Hospital, Gyor, St. Margit Hospital, Budapest, and BAZ County Hospital, Miskolc, with 33 patients participated the international, phase III randomized TAX 306 trial. Between June, 1996 and March, 1998, 429 metastatic breast cancer patients were enrolled in the study. Eligible patients were who had not received prior chemotherapy for advanced disease, and were anthracycline-naive. Objective response rate observed in the AT arm was significantly higher than in the AC arm (ORR: 60% vs. 47%, p=0.008). Time to progression was longer in the AT group (37.1 weeks vs. 31.9 weeks, p=0.0153). Except for higher incidence of neutropenia not requiring dose modification in the AT arm, there were no major differences concerning toxicity. T did not enhance cardiac toxicity induced by A. Conclusion: AT results in significantly higher response rate and longer time to progression than AC in advanced breast cancer, even in patients with unfavourable prognosis.

UR - http://www.scopus.com/inward/record.url?scp=84874975813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874975813&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84874975813

VL - 44

SP - 75

EP - 78

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 1

ER -